Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc. is a U.S.-based biopharmaceutical company focused on therapies for serious rare and ultra-rare genetic diseases. Its portfolio combines approved medicines and clinical-stage programs across biologics, small molecules, AAV gene therapy, and nucleic acid-based candidates, with commercialization in North America, Europe, Latin America, Türkiye, Asia, and selected international markets.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaCommercial medicines for genetically defined rare diseases such as XLH, TIO, MPS VII, LC-FAOD and HoFH.
Gene therapy programs aimed at correcting the underlying cause of inherited metabolic and genetic disorders.
Protein and antibody-based therapies, including approved products and late-stage candidates.
Non-biologic pipeline assets designed for rare disease mechanisms and targeted genetic correction.
Tuotteet
Raportoitu · osuus liikevaihdosta- Products54,8 %
- Royalty45,2 %
Lähde: 10-K FY2025, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.
Asiakkaat
Ultragenyx sells primarily to patients with rare genetic diseases through specialty pharmacies, distributors, and healthcare providers that diagnose and treat these conditions. Demand is driven by the need for chronic, often lifelong treatment in small patient populations where diagnosis, reimbursement, and specialist access are critical.
Patients with XLH, TIO, MPS VII, LC-FAOD, HoFH and other genetic disorders who use the therapies chronically.
Dispense approved products and influence ordering patterns, inventory levels and patient access.
Handle product distribution in smaller international markets where Ultragenyx does not sell directly.
Diagnose rare diseases, prescribe therapies, and manage long-term treatment protocols.
Approve coverage and reimbursement, which strongly affects adoption in orphan drug markets.
Strategia
Ultragenyx focuses on in-licensing promising rare-disease assets and retaining global commercialization rights where possible. Its strategy is to run multiple clinical programs in parallel, use orphan-drug expertise to accelerate development, and build a specialized global commercial footprint for approved therapies.
Diversifies pipeline risk and creates several shots on goal in small markets.
Approved therapies fund the business and establish relationships with rare-disease specialists.
Owning ex-U.S. and U.S. rights where possible increases long-term value capture.
Patient identification, trial design and regulatory execution are key competitive advantages in orphan drugs.
Maantiede
Q1/2026Ultragenyx commercializes its products across North America, the European Union, the United Kingdom, Latin America, Türkiye, Asia, and selected international markets. The company uses its own commercial organization in major markets and third-party distributors in smaller markets, which makes access, reimbursement, and distributor execution important to revenue realization.
Osuus liikevaihdosta, jonka yhtiö raportoi maantieteellisesti.
Riskit
Ultragenyx depends on successful commercialization of a small number of approved products and on clinical and regulatory progress across a concentrated pipeline. The business is exposed to rare-disease market size uncertainty, manufacturing and single-source supply risk, reimbursement pressure, and reliance on third parties for development, distribution and supply.
- Manufacturing and single-source supply disruptionVaikutus: KriittinenTodennäköisyys: Kohtalainen
Drug substance and drug product for many products and candidates come from single-source suppliers.
Kohdistuu: Commercial products and gene therapy pipeline
- Reimbursement and market accessVaikutus: KorkeaTodennäköisyys: Korkea
Orphan drugs often require payer approval and favorable coverage to achieve broad uptake.
Kohdistuu: All approved therapies
- Small addressable patient populationsVaikutus: KorkeaTodennäköisyys: Kohtalainen
Rare-disease markets are inherently limited, so patient identification and penetration are critical to revenue.
Kohdistuu: Approved products and pipeline programs
- Clinical and regulatory failureVaikutus: KorkeaTodennäköisyys: Kohtalainen
Pipeline value depends on successful trials, endpoints, and approvals in complex orphan indications.
Kohdistuu - Distributor and specialty pharmacy concentrationVaikutus: KorkeaTodennäköisyys: Kohtalainen
A considerable portion of sales flows through a small number of intermediaries, affecting sell-through and inventory.
Kohdistuu: Commercial product sales
- Dependence on Kyowa Kirin for Crysvita in major marketsVaikutus: KorkeaTodennäköisyys: Kohtalainen
The company relies on a partner for commercialization and supply in certain markets, including the U.S. and Canada.
Kohdistuu: Crysvita
Kirjanpito
Harkinnanvaraiset erätManagement estimates rebates, chargebacks, returns and other deductions in the period revenue is recorded.
Vaikutus: Can materially affect net product revenue and period-to-period comparability
Buying patterns and seasonality can shift revenue recognition timing and reported sales trends.
Vaikutus: Can create quarter-to-quarter volatility in product revenue
The company records obligations tied to future royalty payments from product sales.
Vaikutus: Affects balance sheet liabilities and interest-like expense recognition
Clinical and commercial supply commitments, including CMO arrangements, require accruals and may be cancelled or accelerated.
Vaikutus: Can affect operating liabilities and cash outflow timing
Development success can trigger contingent payments under in-license and partnership agreements.
Vaikutus: Creates uncertain future obligations and potential expense recognition
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Ventyx Biosciences, Inc.
Pharmaceutical Preparations
United Therapeutics Corporation
UTHR · Pharmaceutical Preparations
United Therapeutics is a U.S.-based biopharmaceutical company focused on therapies for pulmonary arterial hypertension and other serious rare diseases, along with organ manufacturing technologies.
Unicycive Therapeutics, Inc.
UNCY · Pharmaceutical Preparations
Soligenix, Inc
SNGX · Pharmaceutical Preparations
Vincerx Pharma, Inc.
Pharmaceutical Preparations
Agios Pharmaceuticals, Inc
AGIO · Pharmaceutical Preparations
Päivitetty: 24.9.2026